Over the last two decades HIV-1 has spread worldwide and has now surpassed
malaria as the leading cause of infectious disease mortality in adults (htt
p://www.who.int/infectious-disease-report/pages/ch1text.html). The clinical
course and outcome of HIV-1 infection are highly variable among individual
s. Most individuals infected with HIV develop AIDS within 10 years. However
about 1-5% remain relatively healthy for 15 years or more (long-term nonpr
ogressors), while others progress to AIDS within the first 2-3 years after
infection (rapid progressors). A small number of individuals are resistant
to infection, while some individuals appear to eliminate the virus. Factors
that influence susceptibility to infection and rate of disease progression
are a combination of viral, host, and environmental determinants. With few
exceptions, genetic resistance to infectious diseases is likely to involve
a complex array of host genetic effects involving variants that have very
subtle, but significant consequences on gene expression or protein function
. We have gained considerable insight into the genetic effects on HIV-1 dis
ease, yet we likely have uncovered only a fraction of the total picture. Th
e greater our knowledge of various effects on HIV disease, the more likely
we will be able to predict disease outcome on an individual-by-individual b
asis. While this may seem obvious, there is no standard practice of taking
into account the genetic profile (i.e. genotypes at loci known to associate
with rate of AIDS progression) of subjects used in functional studies of i
mmune responsiveness to HIV-1. Here, we propose an approach for assessing o
verall genetic risk on an individual basis, and suggest that this informati
on be considered when selecting comparison groups in studies of immune resp
onses to HIV and/or in the interpretation of data derived from such studies
. Published by Elsevier Science B.V.